Research Topics
| C LewdenSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaborationCharlotte Lewden
INSERM, U897, ISPED, Université Bordeaux Segalen, Bordeaux, France
Int J Epidemiol 41:433-45. 2012..Using data from a large European collaborative study, we aimed to identify the circumstances in which treated HIV-infected individuals will experience similar mortality rates to those of the general population...
CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West AfricaCharlotte Lewden
INSERM, U897, Bordeaux, France
J Acquir Immune Defic Syndr 59:213-9. 2012..CD4-specific rates of mortality in sub-Saharan African adults with high CD4 counts have rarely been estimated. This estimation is useful to the when to start antiretroviral treatment (ART) debate...
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general populationCharlotte Lewden
INSERM, U593, Bordeaux, France
J Acquir Immune Defic Syndr 46:72-7. 2007..To compare mortality rates in combination antiretroviral therapy (cART)-treated HIV-infected adults with mortality in the general population according to the level of CD4 cell count reached and the duration of exposure to cART...
Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic)Charlotte Lewden
INSERM, U897, Bordeaux, France
J Acquir Immune Defic Syndr 48:590-8. 2008..The multicenter national Mortalité 2005 survey aimed at describing the distribution of causes of death among HIV-infected adults in France in 2005 and its changes as compared with 2000...
An example of nonrandom missing data for hepatitis C virus status in a prognostic study among HIV-infected patientsCharlotte Lewden
INSERM U593 exU330, Bordeaux, France
HIV Clin Trials 5:224-31. 2004..To describe information bias due to missing data for hepatitis C (HCV) status in the analysis of factors associated with mortality in HIV-infected patients...
Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimationC Lewden
INSERM U593, ISPED, Bordeaux, France
Epidemiol Infect 134:1345-52. 2006....
Comparison of early CD4 T-cell count in HIV-1 seroconverters in Côte d'Ivoire and France: the ANRS PRIMO-CI and SEROCO cohortsCharlotte Lewden
INSERM, U897, Bordeaux, France
J Acquir Immune Defic Syndr 53:260-5. 2010..We compared CD4+ decline among untreated HIV-1-infected seroconverters living in Côte d'Ivoire (CI) and in France...
How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificatesE Lanoy
INSERM, U720, Paris, France
HIV Med 10:236-45. 2009....
Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing dataCamelia Protopopescu
INSERM, U912 SE4S, 13006 Marseille, France
J Antimicrob Chemother 64:599-606. 2009..The aim of this study was to identify factors associated with non-adherence over a 10 year follow-up of the APROCO-COPILOTE cohort during the maintenance phase of highly active antiretroviral therapy (HAART)...
Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general populationC Lewden
INSERM U330, Bordeaux, France
J Acquir Immune Defic Syndr 26:480-2. 2001..2-3.5) and mortality remained 5.1 times higher (95% CI = 1.0-14.9) than in the general population. Failure of treatment, long-term adverse effects, or less favorable socio-demographic status could explain these trends...
Determinants of smoking cessation attempts among HIV-infected patients results from a hospital-based prospective cohortGaelle Encrenaz
INSERM, U897, CIC EC7, Bordeaux, F 33076 France
Curr HIV Res 8:212-7. 2010..Tobacco smoking is a major modifiable risk factor of these emergent conditions and almost half of these patients are regular smokers in resource-rich countries...
Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases CohorCharlotte Lewden
INSERM U330, Bordeaux, France
J Infect Dis 186:710-4. 2002..Thus, social context plus clinical and biologic data, including the 4-month response to treatment, must be considered in treatment of HIV-infected patients...
[Epidemiology of discordant virologic and immunologic responses in HIV-1 infected patients]R Thiebaut
INSERM E0338 et INSERM U593, ISPED, Universite Bordeaux 2, Bordeaux, France
Med Mal Infect 35:S31-2. 2005
Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohortMarc Arthur Loko
INSERM, U593, Bordeaux, France
Am J Gastroenterol 103:1973-80. 2008..Although an increasing number of noninvasive fibrosis markers are available in HCV-monoinfected patients, data on the performance of these tests in HIV-HCV-coinfected patients are lacking...
High frequency of poor locomotor performance in HIV-infected patientsLaura Richert
INSERM U, Université Bordeaux Segalen, France
AIDS 25:797-805. 2011..To provide up-to-date assessments of locomotor function in HIV-infected patients and to identify potential determinants of impaired function...
Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adultsFideline Collin
Inserm U 897, Universite Victor Segalen Bordeaux 2, 146, rue Leo Saignat, Case 11, 33076 Bordeaux Cedex, France
AIDS 23:1021-4. 2009..6-fold (95% CI = 1.6-8.1) higher in those with hepatitis C virus (HCV) coinfection. Specific monitoring of HCV/HIV-coinfected patients and active promotion of alcohol cessation should be recommended for the prevention of bone fractures...
Causes of death in HIV-infected women: persistent role of AIDS. The 'Mortalité 2000 & 2005' Surveys (ANRS EN19)Mojgan Hessamfar-Bonarek
INSERM, U897, Bordeaux, France
Int J Epidemiol 39:135-46. 2010..Little is known about the causes of death in human immunodeficiency virus (HIV)-infected women in the era of combination antiretroviral therapy (ART)...
Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapyFabrice Bonnet
, , Bordeaux, France
Cancer 101:317-24. 2004..Whereas lethal hemopathies and Kaposi sarcoma are associated with advanced immunosuppression, lethal solid tumors can occur in patients with controlled HIV infection...
Opportunistic infections as causes of death in HIV-infected patients in the HAART era in FranceFabrice Bonnet
Service de Medecine Interne et Maladies Infectieuses, Hôpital Saint André, Bordeaux, France
Scand J Infect Dis 37:482-7. 2005....
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 SurveyFabrice Bonnet
Institut National de la Sante et de la Recherche Medicale INSERM, U593, Bordeaux, France
Clin Infect Dis 48:633-9. 2009....
Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studiesSimon Wandel
Institute of Social and Preventive Medicine ISPM, University of Bern, Finkenhubelweg 11, CH 3012 Bern, Switzerland
Sex Transm Infect 84:i31-i36. 2008..Estimation of the number of people in need of antiretroviral therapy (ART) in resource-limited settings requires information on the time from seroconversion to ART eligibility and from ART eligibility to death...
Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up studyMaria Patrizia Carrieri
INSERM U379, Marseille, France
Antivir Ther 8:585-94. 2003..Priority should be given to interventions aimed to improve adherence in the early months of HAART...
[Causes of death in HIV-infected French drug users, 1995-2000]Charlotte Lewden
INSERM U330, 146, , 33076 Bordeaux Cedex
Ann Med Interne (Paris) 153:2S4-10. 2002..Among IV drug users, improvement in vital prognosis requires to improve management of HCV infection and to take into account socio-economic conditions and other addictive behaviours like alcohol consumption and smoking...
Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDSCharlotte Lewden
INSERM U593 (exU330, , 33076 Bordeaux Cedex, France
Int J Epidemiol 34:121-30. 2005..The prevention of non-AIDS related cancers, especially lung cancer, the management of non-Hodgkin's lymphoma, and of viral hepatitis are also important priorities...
Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcoholDominique Salmon-Ceron
Internal Medicine Department, Cochin Hospital, Paris, France
J Hepatol 42:799-805. 2005..We analyzed the characteristics of HIV infected patients who died from liver disease, focusing on hepatitis virus co-infection...
The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practiceVirginie Villes
INSERM U379, Marseilles, France
Antivir Ther 12:1067-74. 2007..This is especially true for those studies that also consider the possible confounding influence of patient's adherence to treatment...
Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patientsVincent Le Moing
Service des Maladies Infectieuses et Tropicales, , Paris, France
Clin Infect Dis 34:239-47. 2002..89; P=.58). Patients experiencing intolerance should be reassured that changing therapy will probably not be harmful. Multidisciplinary efforts should concentrate on ways to avoid discontinuation of treatment for adherence reasons...
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivityFrancois Raffi
AIDS 22:435-6. 2008
